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Summary: The serum concentration of aminoterminal propeptide of type III procollagen was measured in 44
Egyptian healthy controls and 29 patients with hepatosplenomegaly originating from endemic areas for
schistosomiasis in Egypt. Patients were classified into two main groups according to the histopathological
pattern of the liver biopsy: patients with active schistosomal liver fibrosis and patients with inactive schisto-
somal liver fibrosis. Serum aminoterminal propeptide of type III procollagen levels were elevated in most of
patients with active fibrosis but not in those with inactive schistosomiasis. From the present work, it is
suggested that aminoterminal propeptide of type III procollagen can be used s a marker for active fibrogenesis
in patients with schistosomal liver fibrosis.
Introduction
Schistosomiasis, which affects more than 200 million
people, is the most prevalent form of hepatic fibrosis
worldwide (1). Its pathogenesis is characterized by a
cellular immune response (particularly of the delayed
type) induced by parasite eggs, which are trapped in
the perisinusoidal areas of the host liver, and which
cause a granulomatous reaction and a subsequent
marked periportal fibrosis (2, 3).
Until seVeral years ago, fibrosis was only defined by
an excessive deposition of collagen and other com-
ponents of the extracellular matrix (4). Npw, accord-
ing to Gr essner (5), the definition of fibrosis must take
into account the c mplexity of the changes of the
liver extracellular matrix (6—9), including an increase,
but not all to the same extent, of the contents of most
of the extracellular matrix molecules, some changes
of their microcomposition, and their topographic re-
distrib tion. Among the different collagens present in
the liver (types Ι, ΙΙΪ, IV, V and VI), types I and III
are the most abundant, type III being deposited first,
followed by type I during to fibrotic process (6 — 11).
Since 1979, several attempts have been made to eval-
uate, in biological fluids, the metabolism of human
connective tissue proteins, using radioimmunoassay
techniques (12—13). Much has been published on the
aminoterminal propeptide of type III procollagen.
For serum, the aminoterminal propeptide of type III
procollagen levels are increased in various hepatic
diseases, and this was interpreted in earlier studies in
terms of increased liver collagen synthesis and de-
gradation (14). The relationship between aminoter-
minal propeptide of type III procollagen and ami-
notransferase concentrations in serum suggests in fact
that the peptide may be released during the active
inflammatory phase of the disease by cleavage of
tissue III procollagen, thus reflecting inflammation
and necrosis and not necessarily fibrosis (13, 15).
In schistosomal liver fibrosis, in contrast to other
chronic liver diseases, there is a primary hepatic fi-
brosis with little necrosis. In Order to assess the value
of aminoterminal propeptide of type III procollagen
during evolution of fibrosis, we have measured ami-
noterminal propeptide of type III procollagen levels
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in schistosomal patients with active and inactive fi-
brosis. In endemic areas for schistosomiasis and Hep-
atitis, both diseases can be simultaneously present in
the same patients, which may result in a more severe
form of chronic liver disease. In the present study we




Liver function tests were performed on sera according to the
Standard methods using commercial kits (Boehringer Mann-
heim, Mannheim, Germany). They included: aspartate amino-
transferase, alanine aminotransferase, γ-glutamyl transpepti-
dase, alkaline phosphatase, total bilirubin.
Electrophoresis was also performecl on sera.
Materials and Methods
Subjects
Healthy subjects (members of the medical and non-medical
staff of the Theodor Bilharz Research Institute) were used s
controls (n = 44); they had no history of schistosomiasis or
liver disease.
Patients from endemic areas for schistosomiasis with an hepa-
tosplenic affection were admitted to Theodor Bilharz Research
Institute. All subjects were over 17 years old and had normal
kidney function s demonstrated by normal creatinine clear-
ance. All patients were subjected to complete clinical exami-
nation. They had no evidence of rheumatic diseases. Rectosig-
mo'idoscopic examinations and stool analysis were performed
and showed living or dead Schistosoma mansoni eggs. No Schis-
tosoma haematobium eggs were detected in urine.
Liver biopsies were taken from all patients. Liver sections were
stained with haematoxylin and eosin, and Masson trichrome.
According to the histopathological pattern, only the cases with
pure schistosomal liver fibrosis were selected (n == 29). In pure
schistosomal liver fibrosis, the lobular architecture was pre-
served with no evidence of necrosis or regeneration; the evidence
for schistosomiasis was demonstrated by the presence of eggs,
granuloma or pigments. This group was further divided ac-
cording to the degree of inflammatory cell Infiltration and the
activity of fibrosis (16): in active liver fibrosis, liver sections
showed widening of portal tracts with moderate Infiltration of
chronic inflammatory cells and fibroblasts (n = 19); in inactive
liver fibrosis marked thickening of portal tracts, dense fibrosis
and minimal cellular Infiltration were seen (n = 10).
Relevant clinical data are presented in table l.







































HBsAg, Anti-HBs, HBeAg, Anti-HBe, Anti-HBc and IgM anti-
HBc were assayed by radioimmunoassay (Abbott, Abbott^Park,
USA). No patient had positive HBs antigen and/or chronic
active hepatitis.
Radioimmunoassay of aminoterminal propeptide oftype III pro-
collagen
Bovine p-N-Ill coliagen and aminoterminal propeptide of type
III procollagen (Col 1—3) extracted from fetal calf skin and
rabbit antiserum to purified p-N-lll coliagen (17) were kindly
donated by Dr B. Nusgens, Liege (Belgium). Aminoterminal
prqpeptide of type III procollagen was labelled with 125I by the
chloramine T method and the radioimmunoassay procedure
was modified frpm Pierard et ai. (17) (Hartmann et al., in
preparation) s follows. A dilution of an antiserum (0.1 ml)
capable of binding about 50% of the labelled antigen was
incubated for 24 h at room temperature with 0.05 ml of unla-
belled Standard antigen (Col l — 3) or unknown sample, 0.1 ml
(20000 counts/min) of labelled antigen and 0.25 ml of phos-
phate buffered saline/Tween 0.05 mol/l, pH 7.5 buffer. Foliow-
ing the addition of 0.1 ml of anti-rabbit IgG goat serum diluted
1/20 in 1/200 normal rabbit serum and l ml polyethylene glycol
6000 (15 g/l), the tubes were further incubated for 30 min. The
precipitate was collected by centrifugation at 4000^ fpr 30 min
at 4 °C and the radioactivity measured.
A typical Standard curve is shown in figure 1.
The sensitivity of the assay was l μg/l. The within and between
assays coefficients of Variation were less than 15% (for concen-
trations ranging between 2 and 150 μg/l). The upper limit of
normal values (mean ± 2 SD) was established s 15 μg/l (Harl·








1/32 1/16 1/8 1/4 1/2 1
Liver size is expressed s enlarged (E) or shrunken (S)
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Fig. 1. Typical Standard curve for the determination of human
aminoterminal propeptide of type III procollagen -(·).
Insert: dilution of sera from a healthy subject (D) and
2 patients with schistosomiasis (A, Δ)
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To determine the molecular mass of immunoreactive compo-
nents in serum, we chromatographed 2 ml of normal human
serum on a 1.6 χ 130 cm column of Sephacryl S 500 (Phar-
macia, Uppsala, Sweden) equilibrated in phosphate bufiferfed
saline containing 0.4 ml of TXveen 20 per liter, eluting at a flow
rate of 20 ml/h. We collected and assayed 1.5 ml fractions. This
assay mainly recognized intact aminoterminal propeptide of
type III procollagen and high molecular weight components,
and small degradation products such s Col-1 were recognized
weakly, if at all (fig. 2).
Data were analysed for statistical significance by the unpaired
Mann-Whitney U test. The non-parametric Spearman rank cor-











60 80 100 120 140
Fraction number
160
Fig. 2. Distribution of aminoterminal propeptide of type III
procollagen antigen in normal human serum after chro-
matography on a Sephacryl S 500 column. Inhibition
activity was measured in 1.5 ml individual fractions of
the eluent by direct radioimmunoassay. The column was
calibrated with 125I-l belled type I collagen, non-labeiled
Col 1—3 and Col-1. v0 and vt denote the void and total
volumes of the column.
Results
Results of the liver function tests in patients and
normal controls are summarized in table 2. Serum
levels of aminoterminal pr peptide of type III pro-
collagen in all patients (14.2 ± 6.2 μg/l) (mean + SD)
were higher than those in controls (11.4 ± 2.0 μg/l)
(p = 0.05) (t b. 3 and fig. 3). Patients with active
liver fibrosis had higher aminoterminal propeptide of
type III procollagen values (16.9 ± 5.7 μ̂ /1) than
patients with inactive liver fibrosis (9.1 ±3.5 μg/l)
(p < 0.001).
Tab. 3. Aminoterminal propeptide of type III procollagen levels
in patients with schistosomiasis
Group Aminoterminal Mann-Whitney













* p < ΙΟ'4
** p < ΙΟ"3






















Fig. 3. Serum procollagen III peptide values in patients with
schistosomiasis and in normal controls.
No significant correlation was observed between ami-
noterminal propeptide of type III procollagen and
liver function tests (alanine aminotransferase, aspar-
tate aminotransferase), in partic lar in patients with
active or inactive schistosomal liver fibrosis.
Tab. 2. Liver function tests of the different groups of patients with hepatosplenic schistosomiasis (mean ± S.D.)
Liver test Group of normal controls
(n = 44)
Group of patients with pure schistosomal fibrosis





























n: number of subjects
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Discussion
During schistosomiasis a greatly increased total he-
patic collagen content has been demonstrated (10).
The various types of the deposited collagen have been
characterized by immunocytochemistry at different
stages of schistosome granulomata (18, 19) and thus
collagen typing has become important in the evalua-
tion of the dynamics and prognosis of hepatic fibrosis.
Until recently, histological examination of biopsies
was therefore the only reliable method for determining
the extent and progress of fibrosis in the liver.
In liver diseases, the measurement of aminoterminal
propeptide of type III procollagen in serum by ra-
dioimmunoassay has been proposed äs a non^invasive
parameter. The antigens recognized in the different
aminoterminal propeptide of type III procollagen as-
says were found to be heterogeneous in human serum,
where there are at least 4 immunoreactive forms which
differ in their molecular size (13). Aminoterminal
propeptide of type III procollagen is the intact tri-
meric aminoterminal propeptide of collagen III (Col
l - 3) with a molecular mass of Mr = 45 000 (14, 20).
Its degradation product, Col-1 (MT = 10000), is only
weakly cross-reactive in the conventional aminoter-
minal propeptide of type III procollagen RIA (14).
There are also larger forms recognized by the anti-
bodies: one may represent type procollagen of p-
N-III collagen, the other, somewhat larger than the
propeptide, may be aggregated aminoterminal pro*
peptide of type III procollagen or a degradation prod-
uct of type III procollagen. Moreover their proportion
may vary in patient serum according to the disease
and even during the different phases of a given disease
(13). In addition, these circulating antigens do not
present the same affinity for the antibody äs does
purified aminoterminal propeptide of type III pro-
collagen. Thus, the apparent proportions of the dif-
ferent forms in any serum sample can vary according
to the antisera and the assay conditions used.
The first radipimmunoassay for aminoterminal pro-
peptide of type III procollagen was described by
Rohde (14); the curve slope was less steep than that
for the bovine reference peptide, so the following
improvements were proposed. In order to quantitate
mainly the low molecular forms, Pierard et al. (17)
reported a modified radioimmunoassay using äs
Standard the antigen generated by cleavage of bovine
aminoterminal propeptide of type III procollagen
with bacterial collagenase (Col-1 plus Col-2), while
Rohde et al. (21) introduced an assay using pepsin-
cleaved antibody (Fab fragments), the affinity of the
intact propeptide and its degradation product (Col-1)
to these Fab being nearly identical. In contrast, Risteli
et al. (22) recently used a highly purified human
antigen, and did not detect the small aminoterminal
propeptide of type III procollagen degradation prod-
ucts in serum.
In this study we used the assay of Pierard et al. (17)
with some modifieations, with Col l —3 äs a Standard.
Under the chosen reaction coh'ditiöns (22) (Harmann
et al., in preparation), the reactivity of small degra-
dation products was reduced (fig. 2) and the displace-
ment curves obtained with the antigen and serially
diluted human sera were parallel (fig. 1).
An increased serum aminoterminal propeptide of type
III procollagen might reflect a de novo synthesis of
type III procollagen in the liver, since the amino^
propeptide is partly liberated during the conversion
of procollagen into collagen in stoichiometric
amounts, but it may also reflect the degradation of
tissue type III collagen still containing the aminoter-
minal propeptide (13, 15).
We found that serum aminoterminal propeptide of
type III procollagen was elevated in most of patients
with an active stage of schistosomal liver fibrosis and
not during an inactive stage. Such an increase may
be attributed to an increased collagen synthesis (cor-
related with higher levels of synthesis enzymes) and/
or also to enhancement of collagenolytic activities in
the early stages of schistosomiasis (8, 23). The lower
serum levels observed in schistosomal patients with
inactive liver fibrosis may be related to the absence
of (or minimal) fibrogenic activity (synthesis or deg-
radation) and/or to an increased deposition of type l
collagen rather than type III collagen in the liver
during this stage. Our findings are in agreement with
El-Mohandes et al. (16) and Bolarin et al. (23) for
schistosomiasis, and also with studies on other liver
diseases (14, 24—27), showing that aminoterminal
propeptide of type III procollagen is likely to be a
marker of disease activity. The present data show no
correlation between aminoterminal propeptide of type
III procollagen and aspartate aminotransferase or
alanine aminotransferase in patients with an inactive
or an active stage, in contrast to what has been
observed in other situations (14, 24, 27). However
this result is an agreement with ELMohandes et al.
(16) and Roberts et al. data (28): in patients with
schistosomiasis, increased aminoterminal propeptide
of type III procollagen serum levels were reported,
but without any correlation with necrosis. As serum
aminoterminal propeptide of type 111 procollagen is
likely to be modified during granuJoma resorption
due to increased collagenolytic activities, riatürally (8,
11) or after treatment with praziquantel (29), we have
undertaken follow-up studies of individuals to assess
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the prognostic value of aminoterminal propeptide of
type III procollagen and its usefulness during anti-
schistosomal chemotherapy.
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